- Home
- DHY vs CATX Comparison
DHY vs CATX Comparison
Compare DHY & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$2.81
Company Overview
Basic Information| Metric | DHY | CATX |
|---|---|---|
| Founded | 1998 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.2M | 211.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DHY | CATX |
|---|---|---|
| Price | $2.00 | $2.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.56 |
| AVG Volume (30 Days) | 569.1K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 9.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,075,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.77 | $1.60 |
| 52 Week High | $2.08 | $5.39 |
Technical Indicators
Market Signals| Indicator | DHY | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 55.74 |
| Support Level | $1.98 | $2.67 |
| Resistance Level | $2.03 | $2.88 |
| Average True Range (ATR) | 0.02 | 0.19 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 49.67 | 76.67 |
Price Performance
Historical Comparison DHY
CATX
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.